Zeria Pharmaceutical Co., Ltd. (TYO:4559)
Japan · Delayed Price · Currency is JPY 2,292.00
+22.00 (0.97%)
May 29, 2026, 3:30 PM JST
Zeria Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 11,200 | 12,618 | 9,508 | 7,272 | 5,721 |
Depreciation & Amortization | 7,346 | 7,554 | 7,555 | 6,148 | 5,399 |
Loss (Gain) From Sale of Investments | -168 | 208 | -499 | -19 | -14 |
Loss (Gain) on Equity Investments | 180 | 276 | - | - | - |
Other Operating Activities | -2,735 | -1,039 | -906 | -530 | -864 |
Change in Accounts Receivable | -1,896 | -4,800 | -2,075 | -171 | -2,029 |
Change in Inventory | -3,423 | -1,647 | -863 | -150 | -542 |
Change in Accounts Payable | 520 | 567 | 1,052 | -207 | 284 |
Change in Other Net Operating Assets | -1,069 | -815 | -1,589 | 814 | 995 |
Operating Cash Flow | 9,955 | 12,922 | 12,183 | 13,157 | 8,950 |
Operating Cash Flow Growth | -22.96% | 6.07% | -7.40% | 47.01% | 29.82% |
Capital Expenditures | -2,361 | -1,429 | -2,900 | -2,400 | -1,064 |
Cash Acquisitions | - | - | -623 | - | - |
Sale (Purchase) of Intangibles | -534 | -1,304 | -998 | -257 | -356 |
Investment in Securities | 174 | 1,662 | 473 | 58 | -1,477 |
Other Investing Activities | 20 | 21 | 96 | 25 | 5 |
Investing Cash Flow | -2,701 | -1,050 | -3,952 | -2,574 | -2,892 |
Short-Term Debt Issued | 7 | - | - | 279 | - |
Long-Term Debt Issued | 1,150 | 3,273 | 500 | 500 | 16,158 |
Total Debt Issued | 1,157 | 3,273 | 500 | 779 | 16,158 |
Short-Term Debt Repaid | - | -143 | -560 | - | -13,241 |
Long-Term Debt Repaid | -4,533 | -8,515 | -5,778 | -5,628 | -3,388 |
Total Debt Repaid | -4,533 | -8,658 | -6,338 | -5,628 | -16,629 |
Net Debt Issued (Repaid) | -3,376 | -5,385 | -5,838 | -4,849 | -471 |
Repurchase of Common Stock | - | - | - | -673 | -2,603 |
Common Dividends Paid | -2,110 | -1,976 | -1,935 | -1,590 | -1,538 |
Other Financing Activities | -447 | -395 | -351 | -303 | -229 |
Financing Cash Flow | -5,933 | -7,756 | -8,124 | -7,415 | -4,841 |
Foreign Exchange Rate Adjustments | 2,846 | 749 | 2,402 | 1,346 | 564 |
Miscellaneous Cash Flow Adjustments | - | -2 | 1 | - | 128 |
Net Cash Flow | 4,167 | 4,863 | 2,510 | 4,514 | 1,909 |
Free Cash Flow | 7,594 | 11,493 | 9,283 | 10,757 | 7,886 |
Free Cash Flow Growth | -33.92% | 23.81% | -13.70% | 36.41% | 28.02% |
Free Cash Flow Margin | 8.52% | 13.16% | 12.26% | 15.73% | 13.25% |
Free Cash Flow Per Share | 172.28 | 260.73 | 210.59 | 243.52 | 174.71 |
Cash Interest Paid | 498 | 492 | 446 | 300 | 304 |
Cash Income Tax Paid | 2,737 | 1,001 | 915 | 564 | 874 |
Levered Free Cash Flow | 4,646 | 7,627 | 7,850 | 8,807 | 6,071 |
Unlevered Free Cash Flow | 4,959 | 7,910 | 8,136 | 9,017 | 6,268 |
Change in Working Capital | -5,868 | -6,695 | -3,475 | 286 | -1,292 |